TSLA
Tesla
-- 355.840 NVDA
NVIDIA
-- 138.850 INTC
Intel
-- 23.600 NBIS
NEBIUS
-- 44.490 PLTR
Palantir
-- 119.160 
NEWS
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
Sage Therapeutics has announced a strategic reorganization to support the launch of ZURZUVAE for postpartum depression and focus on pipeline development. The plan includes a workforce reduction of approximately 33%, affecting over 165 employees. This restructuring aims to extend the company's cash runway and position it for long-term growth.
Key changes include:
Leadership team changes with several executives departing
Chris Benecchi expanding role to Chief Operating Officer
Greg Shiferman promoted to Senior VP, General Counsel
Vanessa Procter taking on expanded responsibilities
The reorganization is expected to be completed by Q4 2024, with an anticipated non-recurring charge of $26-28 million. Sage will provide updated cash runway guidance soon.
Key changes include:
Leadership team changes with several executives departing
Chris Benecchi expanding role to Chief Operating Officer
Greg Shiferman promoted to Senior VP, General Counsel
Vanessa Procter taking on expanded responsibilities
The reorganization is expected to be completed by Q4 2024, with an anticipated non-recurring charge of $26-28 million. Sage will provide updated cash runway guidance soon.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
8155
Followers
50
Following
93K
Visitors
Follow
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call